Some of the things that happen in life, when viewed in relation to each other, make Ke Ranhong feel "quite ironic".
Because of the creation of the "medical enjoyment sale", Ke Ranhong, as an innovator in the field of health care, was awarded by the media, "2018 ZhiZhong China annual industry innovation leader". And in the same year, this business almost got her jailed.
The full name of the company is Hangzhou Health Management Co., Ltd, which launched a two-way cross-border medical technology service platform to "provide overseas medical service consulting" to customers and help patients find hospitals and medical experts around the world. In short, it helps domestic patients with "cross-border diagnosis and treatment".
This is a new market blue ocean, but in March 2018, because of the suspected sale of counterfeit drugs, medical enjoyment sale legal representative Ke Ranhong and other people were Hangzhou Public Security Bureau Shangcheng District Branch criminal detention. Because of the breastfeeding period, the mandatory measures for Ke Ranhong changed to bail pending trial.
The prosecution has filed a complaint on January 16, 2019, which has not yet been heard.
From the beginning, this change can be traced back to the "Zhen'an incident" three years ago.
"Zhen'an incident" is a man-made disaster. 2016 February, Shaanxi Province, Shangluo City, Zhen'an County Hospital found that some of the hemodialysis patients were positive for hepatitis C virus antibodies. According to the conclusions of the investigation team, there were 26 patients infected with the hepatitis C virus, and "the cause of the accident was an irregular operation."
China is a low-prevalence area for hepatitis C, which is primarily transmitted through blood. It is generally believed that "Hepatitis B" is a major health hazard lurking in the population, but in fact, hepatitis C is the cause of chronic hepatitis, cirrhosis and hepatocellular carcinoma is an important cause, "Hepatitis C to cirrhosis, liver cancer, the fastest as long as a year," said Ranhong Ke. said.
In the follow-up, some patients contacted MediShare by calling customer service. Ke Ranhong recalled that the officials adopted the traditional treatment program - interferon combined with ribavirin. After the start of treatment, most patients experienced symptoms of drug intolerance, and some patients experienced viral rebound during treatment, "basically a failure."
In fact, patients with hepatitis C already had a more useful treatment option at the time: a combination of sofosbuvir and daclatasvir, which was approved in the United States in 2013 for the treatment of chronic hepatitis C. The following year, another U.S. drug company, Gilead, approved a drug for the treatment of chronic hepatitis C, sofosbuvir. The following year, Bristol-Myers Squibb's original hepatitis C drug daclatasvir was approved.
The combination of these two drugs can completely eliminate all genotypes of the hepatitis C virus. But the three-month regimen, which cost $90,000 for sofosbuvir and $84,000 for daclatasvir at the time, was astronomical for most people.
The patients in the Zhen'an incident came to MediHealth because they were able to "get" cheap generic drugs through the company.
Ke Ranhong is also very difficult, she initially had thought of the best plan, the patients sent directly to the United States or Japan to receive treatment in hospitals. However, the patients could not afford the high cost of treatment, and the official budget was limited to "only 30,000 to 40,000 yuan", which was far from enough.
Because of the patient's poor health and limited funds, the final decision was to contact the Laos Friendship Hospital to provide remote diagnosis and treatment. This, in turn, led to a dispute.
Laos was able to legally produce and use two generic drugs for hepatitis C in 2015. But in China, U.S. originals such as sofosbuvir and daclatasvir were not approved for marketing until 2017.
Before taking over the "Zhenan patients", the medical enjoyment sale provides a model of medical treatment abroad. The company docked the patient and the hospital, the patient went to the Laos Friendship Hospital, get the medicine and return to their own country. In the process, the company provides service work, such as resource matching, and charges a service fee. Together with the diagnostic costs and medication, the patient's expenses "will not exceed 100,000 yuan".
"Zhen'an patients" can not be applied to the model of medical treatment abroad. Wang Cheng recalled that the company thought about whether to intervene in this case for about three months, and finally decided to intervene.
Furthermore, Ke Ranhong thought he was sure. For the second batch, which was more serious, MediHealth sought advice from medical experts in the United States and Japan, and drew on their recommendations and treatment plans. In the end, all three of these patients were cured of Hepatitis C.
Recalling the Zhen'an incident, Ke Ranhong did not deny that she was emotional, she said, and her friends also commented that she was an emotional person.
Ke Ranhong was born in 1975, there are elders in the family engaged in the medical profession, graduated from Zhejiang University of Traditional Chinese Medicine, combined Chinese and Western medicine clinical specialty. Engaged in positions although very mixed, but all related to the pharmaceutical industry. She said that as early as around 2000 she envisioned the introduction of foreign medicines into China.
The logic is simple: since there are new and more effective treatment options, "why bother with the old set?" Ke Ranhong said.
But against all expectations, the approval process for introducing drugs into the country was extremely lengthy. She wasn't going to give up, but instead was inspired to register and set up MediHealth Sales in 2015. The startup capital for this venture came from the proceeds of selling two suites in her name, "one in Hangzhou and one in Shanghai, which she sold to make up 6 million yuan."
Just at that time, the systemic dilemma of drug introduction had not disappeared. Ke Ranhong introduced, the introduction of a new drug, only to declare the information to be handed over three or four, queuing for at least three years. After the project is distributed to the CIQ for testing, it is a long time to enter the clinical safety and effectiveness studies. By 2018, the drug introduction system has seen improvements.
Ke Ranhong smiled rather helplessly, saying that if she had started her business in 2018, she would have been much smoother.
Medical enjoyment sale has never realized a profit, in the beginning of its operation, suffered a "disaster".
After the Zhen'an incident, the medical enjoyment of the sale of the feasibility of remote diagnosis and treatment of this model, "hepatitis C program" from the mode of medical treatment abroad to remote diagnosis and treatment mode. Ke Ranhong introduced, "Hepatitis C program" is one of the company's main business, its earnings accounted for 45% of the company's overall revenue.
Comparatively speaking, in the medical enjoyment of the sale of the company, the higher profits of the project is to provide overseas physical examination, genetic testing, oncology treatment and other services. And the hepatitis C program, although more customers, but the profit margin is low.
Under the overseas medical model, the medical enjoyment sale charges 30,000 yuan. Among them, 20,000 yuan is given to the "Yongzhen Wantai", 10,000 yuan to get their own.
Remote diagnosis mode, the medical enjoyment sale charges 6000 yuan, "most of the customers charge is between 2500 ~ 3500 yuan".
"Yongzhen Wantai" full name Hangzhou Yongzhen Wantai Health Consulting Limited, is a partner of the medical enjoyment sale. Ke Ranhong introduced, she and the head of the Yongzhen Wantai Fan Wenjun know, is a 10-year old friend introduced. Fan Wenjun has lived in Laos for nearly 10 years and has certain connections. The aforementioned partnership with Laos Friendship Hospital was also reached with the support of Fan Wenjun and others.
Ke Ranhong recalled, when the medical enjoyment sale and Yongzhen Wan Thai was originally each contracted with the hospital, respectively, the agent of the hepatitis C program in various regions of China, the two are "parallel structure". But later on, the company gradually became more and more interested in directly participating in the promotion of the hepatitis C program, and in fact became a "subcontractor" under the medical enjoyment of the sale.
Yongzhen Wantai was the first to go wrong.
According to the indictment in the case of Fan Wenjun, on December 26, 2017, an employee of Fan Wenjun's company, Han Mou, was seized by Guangzhou Customs when he brought in a batch of generic drugs. The public security authorities also seized about 14 million yuan worth of bare drugs, raw materials, and outer packaging materials in the warehouse of Fan Wenjun's company, **** involving more than 40 generic drugs that had not obtained drug import approvals.
The fire, soon burned to the medical enjoyment sale here.
On January 20, 2018, Medical Enjoy Sale was investigated. Subsequently, the company's legal representative Ke Ranhong, account manager Chen, as well as three pharmaceutical representatives in the Hangzhou area were criminally detained. Ke Ranhong was changed to bail pending trial on the same day because she was breastfeeding.
In fact, on March 19, 2018, Ke Ranhong, who had only just returned to China after two months of labor and delivery, took the initiative to go to the police station to accept the investigation. She repeatedly emphasized, "I, along with the Medihealth Sales company, am implicated."
According to the indictment, the Hangzhou Shangcheng District People's Procuratorate alleged that Ke Ranhong cooperated with Fan Wenjun to assist Yongzhen Wantai in the sale of sofosbuvir, daclatasvir, and other medicines produced in Laos and not approved for import. Up to the time of the case, the profit *** counted RMB 7.61 million.
The indictment disclosed that since the end of 2015, the medical enjoyment sale launched "telemedicine", the cost of purchasing medicines by the patient to pay directly to the overseas account controlled by Yongzhen Wantai, or through the medical enjoyment sale of the company's public account as well as the personal account of "Tang Zhongying", and then transferred to Yongzhen Wantai, and then transferred to the personal account of Yongzhen Wantai. The fees for the drugs were paid by the patient directly to an offshore account controlled by Yung Zhen Wan Tai, or through the public account of the company and the personal account of "Tang Zhongying" to Yung Zhen Wan Tai. The company received a rebate on the sale of the drugs.
Ke Ranhong's defense attorney, Sun Haiyang, a lawyer at Tianchi Juntai Law Firm, believes that Ke Ranhong does not constitute a crime. She said, Ke Ranhong and medical enjoy sales company did not sell drugs, what they do is to help patients cross the border to seek medical treatment, the fees charged, is the consulting service fee and tracking service fee.
At present, the case of Fan Wenjun has not yet been sentenced after the hearing, and the case of Ke Ranhong has not yet begun.
Ke Ranhong said, she was not aware of the behavior of Yongzhen Wantai's personnel cross-border with drugs, "medical enjoyment of the sale of services to assist the customer to seek medical treatment".
According to Wang Cheng, medical enjoy sale of patients served, is in the domestic hospital subject to diagnosis, submit the relevant certificates and cases to medical enjoy sale, and then docked to the Laos doctor issued a prescription, in the form of EMS, the drugs will be sent to the hands of the patient, "will never pass through our own hands".
In Ke Ranhong, Wang Cheng's understanding, this is called "personal use of drugs", is not provided for in the Drug Administration Law in a special situation, does not constitute a crime, to provide services to the medical enjoyment of the sale of personnel can not be punished for the crime.
The medical enjoyment sale claimed ignorance of Yongzhen Wantai's cross-border drug behavior, "this depends on the evidence, if it is indeed unaware of, the court should be in the sentencing to be taken into account", said Li Sheng.
"I'm not the God of Medicine" was released in August 2018, some people compare Ke Ranhong to a "God of Medicine" to correspond to what happened three years ago, Ke Ranhong laughed and said: "I'm really not the God of Medicine, the God of Medicine in the movie did bring drugs across the border, I did not have my side. "
But the impact of the movie is still great. She came into contact with some of the judiciary, will also talk to her about the movie, commenting that it is very similar to her. Ke Ranhong joked that she had asked the judicial officers, "So you know that the prototype of the God of Medicine, in reality, was not prosecuted, right?"
"Really?" The judicial officer she asked was stunned.
"Yeah." Keran Hong said.
Editing | Zhao Yi zy@nfcmag.com
Typesetting | Law Enforcement Intern Xu Yuejiao
From South Window New Media